In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells

doi:10.1084/jem.160.4.1054

This Article

	Full Text (PDF)
	Alert me when this article is cited

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Ottaway, C. A.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Ottaway, C. A.


Social Bookmarking

	What's this?

ARTICLES

In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells

CA Ottaway

The capacity of T lymphocytes exposed in vitro to the neuropeptide vasoactive intestinal peptide (VIP) to bind VIP in vitro and to migrate to different tissues in vivo has been studied. VIP treatment of T cells resulted in a time- and dose-dependent loss of the ability of T cells to specifically bind radioiodinated VIP. Altered binding was due to a decrease in the expression of cellular receptors for VIP on the treated cells rather than an alteration in the affinity of the cells for the neuropeptide. Alteration of VIP receptor expression was not associated with a change in the expression of Thy-1, Lyt-1, or Lyt-2 surface markers by the treated cells. VIP treatment of T cells in vitro resulted, however, in a dose-dependent decrease in the ability of the treated cells to localize in mesenteric lymph nodes (MLN) and Peyer's patches of recipient animals at early times after cell transfer, and this was due to a selective decrease in the rate of accumulation of the treated cells in these tissues. There was no alteration in the distribution of VIP-treated cells in the blood, spleen, liver, or other major organs of the recipient animals. It is concluded that the presence of VIP receptors on T cells facilitates the entry of T cells into MLN and Peyer's patches in vivo, and it is proposed that this effect is mediated by T cell-VIP interactions in the vicinity of the specialized endothelium of those tissues.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Delgado, M., Pozo, D., Ganea, D. (2004). The Significance of Vasoactive Intestinal Peptide in Immunomodulation. Pharmacol. Rev. 56: 249-290 [Abstract] [Full Text]
Ferone, D., van Hagen, M. P., Kwekkeboom, D. J., van Koetsveld, P. M., Mooy, D. M., Lichtenauer-Kaligis, E., Schönbrunn, A., Colao, A., Lamberts, S. W. J., Hofland, L. J. (2000). Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide in Vitro. J. Clin. Endocrinol. Metab. 85: 1719-1726 [Abstract] [Full Text]
Xia, M., Sreedharan, S. P., Bolin, D. R., Gaufo, G. O., Goetzl, E. J. (1997). Novel Cyclic Peptide Agonist of High Potency and Selectivity for the Type II Vasoactive Intestinal Peptide Receptor. J. Pharmacol. Exp. Ther. 281: 629-633 [Abstract] [Full Text]
Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., Valent, P. (1994). Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. NEJM 331: 1116-1121 [Abstract] [Full Text]